Prostaglandin E1: Difference between revisions

No edit summary
 
(14 intermediate revisions by 8 users not shown)
Line 1: Line 1:
==General==
==General==
*Type:  
*AKA: aloprostadil
*Dosage Forms:
*Type: smooth muscle relaxer, vasodilator
*Common Trade Names:  
*Dosage Forms: intravenous, penile injection, penile suppository
*Common Trade Names: [https://alprostadil.org Alprostadil], Prostin VR, Caverject, Muse, Edex
*Uses: maintenance of [[patent ductus arteriosus]] in neonates with duct-dependent congenital heart defects; treatment of erectile dysfunction in adults


==Adult Dosing==
==Adult Dosing==


==Pediatric Dosing==
==Pediatric Dosing<ref> Donofrio MT, Moon-Grady AJ, Hornberger LK, Copel JA, Sklansky MS, Abuhamad A, Cuneo BF, Huhta JC, Jonas RA, Krishnan A, Lacey S, Lee W, Michelfelder EC Sr, Rempel GR, Silverman NH, Spray TL, Strasburger JF, Tworetzky W, Rychik J. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. American Heart Association Adults With Congenital Heart Disease Joint Committee of the Council on Cardiovascular Disease in the Young and Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Council on Cardiovascular and Stroke Nursing.Circulation. 2014 May 27;129(21):2183-242. doi: 10.1161/01.cir.0000437597.44550.5d. Epub 2014 Apr 24.</ref>==
Start infusion at 0.05 mcg/kg/min IV and titrate up to 0.1 mcg/kg/min, monitoring for hypotension (and apnea)<ref> Donofrio MT, Moon-Grady AJ, Hornberger LK, Copel JA, Sklansky MS, Abuhamad A, Cuneo BF, Huhta JC, Jonas RA, Krishnan A, Lacey S, Lee W, Michelfelder EC Sr, Rempel GR, Silverman NH, Spray TL, Strasburger JF, Tworetzky W, Rychik J. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. American Heart Association Adults With Congenital Heart Disease Joint Committee of the Council on Cardiovascular Disease in the Young and Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Council on Cardiovascular and Stroke Nursing.Circulation. 2014 May 27;129(21):2183-242. doi: 10.1161/01.cir.0000437597.44550.5d. Epub 2014 Apr 24.</ref>
*Start infusion at 0.05 mcg/kg/min IV
 
**Titrate to 0.1 mcg/kg/min as tolerated, monitoring for hypotension (and apnea)
See [[Tetralogy of fallot]]


==Special Populations==
==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]:
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C
*Lactation:
*Lactation: infant risk cannot be ruled out
*Renal Dosing
*Renal Dosing
**Adult
**Adult
Line 25: Line 26:


==Adverse Reactions==
==Adverse Reactions==
*Hypotension
*Beware of three common side effects that may require further resuscitation<ref>Martin RJ et al. Pathophysiologic Mechanisms Underlying Apnea of Prematurity. NeoReviews Vol.3 No.4 April 2002.</ref><ref>Segar JL. Protocol for Use of Prostaglandin E. University of Iowa Stead Family Children's Hospital. Accessed Dec 2016. https://uichildrens.org/health-library/protocol-use-prostaglandin-e?id=234424</ref>:
*Bradycardia
**Apnea (12%), which requires respiratory monitoring with ETCO2 capnography, potential mechanical ventilation, and/or ALS/PALS transport if needing transfer to higher level of care
*Seizures
**Peripheral flushing with or without hypotension (10%), which requires fluid resuscitation
*Apnea
**[[Fever]] (14%)
*Others:
**[[Hypotension]]
**[[Bradycardia]]
**[[Seizures]]


==Pharmacology==
==Pharmacology==
*Half-life:  
*Half-life: 5-10m
*Metabolism:  
*Metabolism: Lung
*Excretion:  
*Excretion: Renal
*Mechanism of Action:
*Mechanism of Action: synthetic of endogenous prostaglandin
 
==Comments==
*Cyanotic neonates with ductal-dependent lesions typically respond within 10-15 minutes, but may not show response until several hours after the start of infusion.


==See Also==
==See Also==
*[[Tetralogy of fallot]]


==Sources==
==References==
<references/>


<references/>
[[Category:Pharmacology]]
[[Category:Drugs]]
[[Category:Pediatrics]]
[[Category:Cardiology]]

Latest revision as of 22:09, 23 September 2019

General

  • AKA: aloprostadil
  • Type: smooth muscle relaxer, vasodilator
  • Dosage Forms: intravenous, penile injection, penile suppository
  • Common Trade Names: Alprostadil, Prostin VR, Caverject, Muse, Edex
  • Uses: maintenance of patent ductus arteriosus in neonates with duct-dependent congenital heart defects; treatment of erectile dysfunction in adults

Adult Dosing

Pediatric Dosing[1]

  • Start infusion at 0.05 mcg/kg/min IV
    • Titrate to 0.1 mcg/kg/min as tolerated, monitoring for hypotension (and apnea)

Special Populations

  • Pregnancy Rating: C
  • Lactation: infant risk cannot be ruled out
  • Renal Dosing
    • Adult
    • Pediatric
  • Hepatic Dosing
    • Adult
    • Pediatric

Contraindications

  • Allergy to class/drug

Adverse Reactions

  • Beware of three common side effects that may require further resuscitation[2][3]:
    • Apnea (12%), which requires respiratory monitoring with ETCO2 capnography, potential mechanical ventilation, and/or ALS/PALS transport if needing transfer to higher level of care
    • Peripheral flushing with or without hypotension (10%), which requires fluid resuscitation
    • Fever (14%)
  • Others:

Pharmacology

  • Half-life: 5-10m
  • Metabolism: Lung
  • Excretion: Renal
  • Mechanism of Action: synthetic of endogenous prostaglandin

Comments

  • Cyanotic neonates with ductal-dependent lesions typically respond within 10-15 minutes, but may not show response until several hours after the start of infusion.

See Also

References

  1. Donofrio MT, Moon-Grady AJ, Hornberger LK, Copel JA, Sklansky MS, Abuhamad A, Cuneo BF, Huhta JC, Jonas RA, Krishnan A, Lacey S, Lee W, Michelfelder EC Sr, Rempel GR, Silverman NH, Spray TL, Strasburger JF, Tworetzky W, Rychik J. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. American Heart Association Adults With Congenital Heart Disease Joint Committee of the Council on Cardiovascular Disease in the Young and Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Council on Cardiovascular and Stroke Nursing.Circulation. 2014 May 27;129(21):2183-242. doi: 10.1161/01.cir.0000437597.44550.5d. Epub 2014 Apr 24.
  2. Martin RJ et al. Pathophysiologic Mechanisms Underlying Apnea of Prematurity. NeoReviews Vol.3 No.4 April 2002.
  3. Segar JL. Protocol for Use of Prostaglandin E. University of Iowa Stead Family Children's Hospital. Accessed Dec 2016. https://uichildrens.org/health-library/protocol-use-prostaglandin-e?id=234424